KEI comments on NIH exclusive license to Mevox for Measles and Mumps vaccine
The comments focusing on geographic scope, pricing, manufacturing know-how and transparency. June 2, 2021 Daniel Lee, J.D., Technology Transfer and Patent Specialist, National Institute of Allergy and Infectious Diseases Technology Transfer and Intellectual Property Office Via daniel.lee5@nih.gov Re: Prospective Grant… Continue Reading